Galecto Inc GLTO:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 6:29 PM EDT
0.69quote price arrow up+0.0147 (+2.1614%)
Volume
18,540
Close
0.6801quote price arrow up+0.0046 (+0.681%)
Volume
28,267
52 week range
0.50 - 3.70
Loading...
  • Open0.675
  • Day High0.6941
  • Day Low0.66
  • Prev Close0.6755
  • 52 Week High3.70
  • 52 Week High Date07/26/23
  • 52 Week Low0.50
  • 52 Week Low Date11/01/23

Key Stats

  • Market Cap18.439M
  • Shares Out27.11M
  • 10 Day Average Volume0.09M
  • Dividend-
  • Dividend Yield-
  • Beta1.27
  • YTD % Change-5.54

KEY STATS

  • Open0.675
  • Day High0.6941
  • Day Low0.66
  • Prev Close0.6755
  • 52 Week High3.70
  • 52 Week High Date07/26/23
  • 52 Week Low0.50
  • 52 Week Low Date11/01/23
  • Market Cap18.439M
  • Shares Out27.11M
  • 10 Day Average Volume0.09M
  • Dividend-
  • Dividend Yield-
  • Beta1.27
  • YTD % Change-5.54

RATIOS/PROFITABILITY

  • EPS (TTM)-1.15
  • P/E (TTM)-0.59
  • Fwd P/E (NTM)-0.60
  • EBITDA (TTM)-28.45M
  • ROE (TTM)-78.56%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date07/29/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Galecto Inc

 

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Galecto, Inc. is a clinical-stage biotechnology company. The Company is focused on developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and fibrotic diseases. The Company’s initial focus is on the development of small molecule inhibitors of galectin-3 and lysyl oxidase-like 2 (LOXL2). It is developing GB0139 for the treatment of Idiopathic Pulmonary Fibrosis (IPF), a life-threatening progressive...
Carl Goldfischer M.D.
Independent Chairman of the Board
Hans Schambye M.D., Ph.D.
President, Chief Executive Officer, Director
Anders Pedersen
Chief Operating Officer
Jonathan Freve CPA
Chief Financial Officer
Garrett Winslow
General Counsel, Corporate Secretary
Address
75 State Street, Suite 100
Boston, MA
02109
United States

Top Peers

SYMBOLLASTCHG%CHG
NRBO
NeuroBo Pharmaceuticals Inc
3.65+0.40+12.31%
SRZN
Surrozen Inc
9.79-0.97-9.01%
EVAX
Evaxion Biotech A/S
4.01-0.16-3.84%
PMCB
PharmaCyte Biotech Inc
2.18+0.06+2.83%
RNXT
RenovoRx Inc
1.23+0.02+1.65%